378 related articles for article (PubMed ID: 26920060)
41. Salvianolic acid A, a novel PI3K/Akt inhibitor, induces cell apoptosis and suppresses tumor growth in acute myeloid leukemia.
Pei R; Si T; Lu Y; Zhou JX; Jiang L
Leuk Lymphoma; 2018 Aug; 59(8):1959-1967. PubMed ID: 29164984
[TBL] [Abstract][Full Text] [Related]
42. Targeting sphingosine kinase-1 to inhibit melanoma.
Madhunapantula SV; Hengst J; Gowda R; Fox TE; Yun JK; Robertson GP
Pigment Cell Melanoma Res; 2012 Mar; 25(2):259-74. PubMed ID: 22236408
[TBL] [Abstract][Full Text] [Related]
43. The Sphingosine Kinase 2 Inhibitor ABC294640 Restores the Sensitivity of BRAFV600E Mutant Colon Cancer Cells to Vemurafenib by Reducing AKT-Mediated Expression of Nucleophosmin and Translationally-Controlled Tumour Protein.
Grbčić P; Eichmann TO; Kraljević Pavelić S; Sedić M
Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639107
[TBL] [Abstract][Full Text] [Related]
44. Curcumin stimulates reactive oxygen species production and potentiates apoptosis induction by the antitumor drugs arsenic trioxide and lonidamine in human myeloid leukemia cell lines.
Sánchez Y; Simón GP; Calviño E; de Blas E; Aller P
J Pharmacol Exp Ther; 2010 Oct; 335(1):114-23. PubMed ID: 20605902
[TBL] [Abstract][Full Text] [Related]
45. Characterization of N,N,-dimethyl-D-erythro-sphingosine-induced apoptosis and signaling in U937 cells: independence of sphingosine kinase inhibition.
Kim HL; Sacket SJ; Han M; Im DS
Prostaglandins Other Lipid Mediat; 2008 Jun; 86(1-4):18-25. PubMed ID: 18316219
[TBL] [Abstract][Full Text] [Related]
46. Apoptosis induction of human leukemia cells by Streptomyces sp. SY-103 metabolites through activation of caspase-3 and inactivation of Akt.
Jeong SY; Han MH; Jin CY; Kim GY; Choi BT; Nam TJ; Kim SK; Choi YH
Int J Mol Med; 2010 Jan; 25(1):31-40. PubMed ID: 19956899
[TBL] [Abstract][Full Text] [Related]
47. T-LAK cell-originated protein kinase presents a novel therapeutic target in FLT3-ITD mutated acute myeloid leukemia.
Alachkar H; Mutonga M; Malnassy G; Park JH; Fulton N; Woods A; Meng L; Kline J; Raca G; Odenike O; Takamatsu N; Miyamoto T; Matsuo Y; Stock W; Nakamura Y
Oncotarget; 2015 Oct; 6(32):33410-25. PubMed ID: 26450903
[TBL] [Abstract][Full Text] [Related]
48. Targeting sphingosine kinase 1 inhibits Akt signaling, induces apoptosis, and suppresses growth of human glioblastoma cells and xenografts.
Kapitonov D; Allegood JC; Mitchell C; Hait NC; Almenara JA; Adams JK; Zipkin RE; Dent P; Kordula T; Milstien S; Spiegel S
Cancer Res; 2009 Sep; 69(17):6915-23. PubMed ID: 19723667
[TBL] [Abstract][Full Text] [Related]
49. Mechanistic insights into the antileukemic activity of hyperforin.
Billard C; Merhi F; Bauvois B
Curr Cancer Drug Targets; 2013 Jan; 13(1):1-10. PubMed ID: 22924417
[TBL] [Abstract][Full Text] [Related]
50. Repression of sphingosine kinase (SK)-interacting protein (SKIP) in acute myeloid leukemia diminishes SK activity and its re-expression restores SK function.
Ghazaly EA; Miraki-Moud F; Smith P; Gnanaranjan C; Koniali L; Oke A; Saied MH; Petty R; Matthews J; Stronge R; Joel SP; Young BD; Gribben J; Taussig DC
J Biol Chem; 2020 Apr; 295(16):5496-5508. PubMed ID: 32161116
[TBL] [Abstract][Full Text] [Related]
51. Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia.
Chapuis N; Tamburini J; Green AS; Vignon C; Bardet V; Neyret A; Pannetier M; Willems L; Park S; Macone A; Maira SM; Ifrah N; Dreyfus F; Herault O; Lacombe C; Mayeux P; Bouscary D
Clin Cancer Res; 2010 Nov; 16(22):5424-35. PubMed ID: 20884625
[TBL] [Abstract][Full Text] [Related]
52. The Tumorigenic Effect of Sphingosine Kinase 1 and Its Potential Therapeutic Target.
Wang X; Sun Y; Peng X; Naqvi SMAS; Yang Y; Zhang J; Chen M; Chen Y; Chen H; Yan H; Wei G; Hong P; Lu Y
Cancer Control; 2020; 27(1):1073274820976664. PubMed ID: 33317322
[TBL] [Abstract][Full Text] [Related]
53. Combination screening in vitro identifies synergistically acting KP372-1 and cytarabine against acute myeloid leukemia.
Österroos A; Kashif M; Haglund C; Blom K; Höglund M; Andersson C; Gustafsson MG; Eriksson A; Larsson R
Biochem Pharmacol; 2016 Oct; 118():40-49. PubMed ID: 27565890
[TBL] [Abstract][Full Text] [Related]
54. Acid ceramidase is upregulated in AML and represents a novel therapeutic target.
Tan SF; Liu X; Fox TE; Barth BM; Sharma A; Turner SD; Awwad A; Dewey A; Doi K; Spitzer B; Shah MV; Morad SA; Desai D; Amin S; Zhu J; Liao J; Yun J; Kester M; Claxton DF; Wang HG; Cabot MC; Schuchman EH; Levine RL; Feith DJ; Loughran TP
Oncotarget; 2016 Dec; 7(50):83208-83222. PubMed ID: 27825124
[TBL] [Abstract][Full Text] [Related]
55. Gallic acid targets acute myeloid leukemia via Akt/mTOR-dependent mitochondrial respiration inhibition.
Gu R; Zhang M; Meng H; Xu D; Xie Y
Biomed Pharmacother; 2018 Sep; 105():491-497. PubMed ID: 29883944
[TBL] [Abstract][Full Text] [Related]
56. Melittin induces Bcl-2 and caspase-3-dependent apoptosis through downregulation of Akt phosphorylation in human leukemic U937 cells.
Moon DO; Park SY; Choi YH; Kim ND; Lee C; Kim GY
Toxicon; 2008 Jan; 51(1):112-20. PubMed ID: 17936321
[TBL] [Abstract][Full Text] [Related]
57. The pan-class I phosphatidyl-inositol-3 kinase inhibitor NVP-BKM120 demonstrates anti-leukemic activity in acute myeloid leukemia.
Allegretti M; Ricciardi MR; Licchetta R; Mirabilii S; Orecchioni S; Reggiani F; Talarico G; Foà R; Bertolini F; Amadori S; Torrisi MR; Tafuri A
Sci Rep; 2015 Dec; 5():18137. PubMed ID: 26674543
[TBL] [Abstract][Full Text] [Related]
58. Biological characterization of 3-(2-amino-ethyl)-5-[3-(4-butoxyl-phenyl)-propylidene]-thiazolidine-2,4-dione (K145) as a selective sphingosine kinase-2 inhibitor and anticancer agent.
Liu K; Guo TL; Hait NC; Allegood J; Parikh HI; Xu W; Kellogg GE; Grant S; Spiegel S; Zhang S
PLoS One; 2013; 8(2):e56471. PubMed ID: 23437140
[TBL] [Abstract][Full Text] [Related]
59. Phenethyl isothiocyanate exhibits antileukemic activity in vitro and in vivo by inactivation of Akt and activation of JNK pathways.
Gao N; Budhraja A; Cheng S; Liu EH; Chen J; Yang Z; Chen D; Zhang Z; Shi X
Cell Death Dis; 2011 Apr; 2(4):e140. PubMed ID: 21472003
[TBL] [Abstract][Full Text] [Related]
60. β-Catenin and AKT are promising targets for combination therapy in acute myeloid leukemia.
Wang L; You LS; Ni WM; Ma QL; Tong Y; Mao LP; Qian JJ; Jin J
Leuk Res; 2013 Oct; 37(10):1329-40. PubMed ID: 23867056
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
